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Abstract
Background: RGD-motif acts as a specific integrins-ligand and regulates a variety of cell-functions via extracellular 
action affecting cell-adhesion properties. However, increasing evidence identifies additional RGDS-functions at 
intracellular level. Previous reports show RGDS-internalization in endothelial cells, cardiomyocytes and lymphocytes, 
indicating intracellular targets such as caspase-8 and caspase-9, and suggest RGDS specific activity at cytoplasmic 
level. Given the role RGDS-peptides play in controlling proliferation and apoptosis in several cell types, investigating 
intracellular targets of RGDS in melanoma cells may un-reveal novel molecular targets and key pathways, potentially 
useful for a more effective approach to melanoma treatment.
Results: In the present study we show for the first time that RGDS-peptide is internalized in melanoma cells in a time-
dependent way and exerts strong anti-proliferative and pro-apoptotic effects independently from its extracellular anti-
adhesive action. RGES control-peptide did not show biological effects, as expected; nevertheless it is internalized, 
although with slower kinetics. Survivin, a known cell-cycle and survival-regulator is highly expressed in melanoma cells. 
Co-immunoprecipitation assays in cell lysates and overlay assays with the purified proteins showed that RGDS interacts 
with survivin, as well as with procaspase-3, -8 and -9. RGDS-peptide binding to survivin was found to be specific, at 
high affinity (Kd 27.5 μM) and located at the survivin C-terminus. RGDS-survivin interaction appeared to play a key role, 
since RGDS lost its anti-mitogenic effect in survivin-deprived cells with a specific siRNA.
Conclusions: RGDS inhibits melanoma growth with an adhesion-independent mechanism; it is internalized in 
melanoma cells and specifically interacts with survivin. The present data may indicate a novel role of RGDS-containing 
peptides physiologically released from the extracellular matrix and may suggest a possible novel anti-proliferation 
strategy in melanoma.
Background
RGD (Arg-Gly-Asp) motif is largely investigated as medi-
ator of cell adhesion to extracellular matrix and to cells,
via cell-surface receptors named integrins. These recep-
tors belong to a large family of twenty-four heterodimeric
members. Several integrins, including αvβ3, α5β1, αvβ5,
αvβ6 and αIIbβ3, recognize the RGD motif present in vari-
ous ECM proteins such as fibronectin, vitronectin, lami-
nin, fibrinogen, von Willebrand factor, osteopontin,
thrombospondin, and collagen [1] as well as in disinteg-
rins; others including α1β1, α2β1, α10β1, and α11β1, interact
with the matrix in a RGD-independent manner [2-4].
Integrins activation triggers different signals regulating
cell adhesion, migration, survival, apoptosis [1,5,6] as well
as processes such as angiogenesis, thrombosis and osteo-
porosis [7-9]. Further, integrins control the interaction of
tumor cells with the surrounding environment, with a
direct effect on cell proliferation, migration, metastatic
dissemination, invasion, cell survival [10,11]. RGD motif-
containing peptides bind integrin receptors with high
affinity and inhibit cell adhesion by competing the integ-
rins/matrix interaction leading to anti-inflammatory,
anti-coagulant and anti-metastatic effects, as well as anti-
angiogenic effects [12-15]. RGD peptides are also
involved in tumor and endothelial cells-targeting via the
αvβ3 receptors [16-19] as well as in noninvasive tumor
imaging, targeting and radio-treatment [20].
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RGD-containing peptides inhibit cell growth by induc-
ing cells-detachment from extracellular matrix and adhe-
sion-dependent apoptosis, named anoikis [21]. An
additional mechanism, previously investigated by us and
Others, involves RGD peptides cell-internalization, intra-
cellular targeting and direct activation of caspase-3, cas-
pase-8 or caspase-9 in lymphocytes, cardiomyocytes,
endothelial cells and chondrocytes, leading to apoptosis
most-likely via an integrin-independent mechanism
[3,22-24]. These findings suggest that RGD motif, in
addition to targets exposed onto the external surface of
cell membrane, recognizes intracellular targets (namely
caspases), leading to procaspase auto-processing and
activation.
Survivin is a member of the Inhibitor of Apoptosis Pro-
tein (IAPs) family; it is involved in multiple functions,
including control of cell division, apoptosis and cellular
response to stress [25]. Survivin is selectively expressed
during development and in proliferating cells; it increases
during G1 cell-phase and reaches a peak-level at G2-M
phase. Survivin expression level is very low or undetect-
able in most differentiated tissues, in the absence of stress
conditions, while normally it is expressed in thymus,
basal colonic epithelium, endothelial cells and neural
stem cells during angiogenesis [25]. Survivin plays a criti-
cal role in cancer biology; it is selectively expressed in
transformed cells and in most cancers as breast, lung,
pancreatic and colon carcinomas, haematological
tumors, sarcomas and neuroblastoma. Further, it is
expressed in melanocytic nevi, melanoma metastatic
lesions and invasive melanomas, but not in normal mel-
anocytes [26]. Survivin is a survival factor for cancer cells
and its over-expression correlates with unfavorable prog-
nosis, high recurrence risk, metastasis, high resistance to
both chemo- and radio-therapy [27]. Due to its role in
cancer resistance to apoptotic stimuli, survivin has been
proposed as a potential target for anticancer therapies
based on antisense oligonucleotides, small interfering
RNAs, ribozymes and dominant negative mutants [28-
31].
In the present study we investigated for the first time
intracellular targets of RGDS peptide in human meta-
static melanoma cells and identified survivin as a novel
direct target of RGDS molecule.
Results
RGDS effect on SK-MEL-110 proliferation and apoptosis
As we and others previously demonstrated [2-4], cell
adhesion to collagen-IV is RGD-independent. We further
confirmed such observation on SK-MEL-110 cells
(unpublished data). We therefore investigated cells
seeded onto collagen IV-coated plastic throughout the
whole study, in order to investigate RGDS-effects inde-
pendently of its anti-adhesive action. Melanoma cells
proliferation induced by FGF-2 was significantly reduced
in the presence of RGDS (Figure 1A top) (46 ± 16% inhi-
bition, p < 0.005) at 500 μg/ml, indicating that, despite the
p r e s e n c e  o f  t h e  s t r o n g  s u r v i v a l  f a c t o r  F G F - 2 ,  R G D S
exerts a potent anti-proliferative effect on SK-MEL-110
cells, independently of its anti-adhesive properties. Con-
trol peptide RGES had no anti-proliferative effect, as
expected. The effect is shown in one representative field
(Figure 1A bottom).
RGDS-treated cells were stained with propidium iodide
(PI) and cell cycle was investigated. RGDS-treatment (48
h, 500 μg/ml) increased the percentage of cells in sub-G1-
phase from 3% (with FGF-2 alone) to 13.2% (with FGF-2
and RGDS) (Figure 1B top and bottom), indicating that
RGDS may induce apoptosis in melanoma cells, in the
presence of FGF-2. RGDS-treatment also increased num-
ber of cells in G1-phase, vs control (77% vs 67%), and
markedly reduced cell-number in S (3.5% vs 8.7%) and in
G2-phase (9% vs 16%) (Additional file 1).
RGDS cell internalization
We then investigated whether RGDS is internalized into
SK-MEL-110, by exploiting different experimental
approaches. RGDS internalization in live cells was quan-
tified by FACS analysis. The biotinylated peptide entered
into melanoma cells in a time-dependent manner (Figure
1C); positive cells reached about 40% of total cells at 24 h
incubation. RGES internalized with slower kinetics,
reaching about 30% of positive cells at 24 h (i.e., 25% less
than RGDS). RGDS internalization was markedly higher
in melanoma cells vs HUVEC (Additional file 2). RGDS
internalization was also measured in cytoplasmic extracts
of SK-MEL-110 exposed to increasing doses of bt-RGDS
for 24 h at 37°C or biotin alone as control (Figure 2A).
Internalization was measured by densitometry and was
inhibited by an excess of not-biotinylated RGDS, indicat-
ing a specific internalization accounting for about 60% of
the total internalization (Figure 2B). Confocal microscopy
further supported these results, indicating a mostly cyto-
plasmic intracellular localization (Figure 2C) at 24 h
treatment.
RGDS-survivin interaction
The observation that RGDS is able to internalize into
melanoma cells raised the question whether RGDS may
recognize intracellular targets. Biotinylated-RGDS (bt-
RGDS) was found to directly interact with cytoplasmic
extracts and such binding was strongly inhibited by an
excess of unlabeled-RGDS (Figure 3A), suggesting that
RGDS recognizes specific targets in cytoplasmic lysates.
Survivin is known to be highly expressed in tumors and
melanoma playing a key role in survival control [32,33].
In SK-MEL-110 melanoma cells it is expressed at levelsAguzzi et al. Molecular Cancer 2010, 9:84
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higher than endothelial cells (HUVEC) or melanocytes
(Additional file 3).
We thus hypothesized a functional interaction between
survivin and intracellular RGDS. RGD peptides have
been reported by us and by Others to interact with intra-
cellular targets such as pro-caspase-3, caspase-8 and cas-
pase-9 in other cell types [3,22,23]. We hypothesized that
RGDS may recognize additional intracellular targets,
namely survivin. Cytoplasmic lysates of growing SK-
MEL-110, were incubated with bt-RGDS-coated dyna-
beads. Proteins interacting with RGDS were then
revealed by SDS-page and western blotting and were
identified with specific detecting-antibodies, as pro-cas-
pase-8, pro-caspase-9, pro-caspase-3 and survivin, while
RGDS did not interact with pro-caspase-1. Pre-incubat-
ing lysates with not-biotinylated RGDS abolished interac-
tion of bt-RGDS with survivin, caspase-3, caspase-8 and
caspase-9, indicating a specific binding; such conclusion
was further supported by the observation that bt-RGES
control peptide is not able to bind with any tested intrac-
ellular protein (Figure 3B). Direct binding of RGDS with
intracellular proteins was further investigated in overlay
assays by direct immobilization of several different pro-
teins onto nitrocellulose membrane. Labeled RGDS was
found to directly interact with precursor- and active-cas-
pase-9 and with recombinant survivin and this binding
was specifically inhibited, at least in part, in the presence
of an excess of unlabeled RGDS. BSA, fibronectin or
Figure 1 SK-MEL-110 proliferation and apoptosis. A: SK-MEL-110 seeded on collagen-IV (50 μg/ml) were treated for 48 h with RGDS or RGES (500 
μg/ml) in the presence of FGF-2 (10 ng/ml). Data are expressed as mean ± SD of 5 experiments carried out in duplicate. Representative images are 
reported. B: SK-MEL-110 apoptosis was quantified by FACS analysis of PI-stained cells after 48 h RGDS treatment (500 μg/ml) (p < 0.05 vs FGF-2). Three 
independent experiments were performed and quantified; one representative experiment is shown. C: Biotinylated-RGDS and RGES internalization in 
SK-MEL-110 was measured by FACS. Cells were treated for different time points (2, 6, 16 and 24 h) with bt-RGDS or bt-RGES; internalization was re-
vealed by PE-avidin. Three independent experiments were performed.Aguzzi et al. Molecular Cancer 2010, 9:84
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active caspase-1 did not interact with RGDS (Figure 3C).
To further investigate such interaction, increasing doses
of recombinant survivin (0.3 to 5 μg) were immobilized
onto nitrocellulose membrane and incubated with the bt-
RGDS. RGDS bound survivin in a concentration-depen-
dent and saturable manner. Specific binding was com-
puted by subtracting nonspecific binding from the total
binding (Figure 4A top and bottom). As a further
approach, a solid phase assay was carried out. Recombi-
nant GST (as control), GST-Full length survivin, GST-N-
terminus-survivin and GST-C-terminus-survivin were
immobilized onto plastic and incubated with increasing
concentrations of bt-RGDS in the presence or in the
absence of an excess of unlabeled RGDS. Under such con-
ditions RGDS bound Full-length survivin and C-Termi-
nus-survivin in a dose-dependent and saturable way. A
Kd of 27.5 μM and 30 μM, respectively and a Bmax of
0.61 and 0.56, for the binding to Full-length and C-termi-
nus, respectively (Figure 4B), were computed according
to the one-site binding curve-fit equation (1). In contrast,
RGDS did not bind the GST-N-terminus fragment (Kd of
-161 and Bmax of -0.0079). These data suggested that
RGDS-survivin interaction occurs at a single site at the
C-Terminus region of survivin.
Survivin small interference-RNA
The reported results demonstrate a specific interaction of
RGDS and survivin. We then investigated whether sur-
vivin mediates RGDS effects on cell proliferation/sur-
vival. To this aim survivin was silenced in SK-MEL-110
and cells were treated with RGDS for 48 h. SiGLO Lamin
A/C siRNA was used as positive control of transfection
efficiency. Survivin silencing was confirmed by western
blotting and showed complete protein down-regulation
(Figure 5A top) and induced high mortality in SK-MEL-
110 (35%, data not shown), as expected. Under such sur-
vivin-deprivation conditions, FGF-2 has a reduced sur-
vival effect, as expected, and RGDS completely looses its
inhibitory effect (Figure 5A bottom), suggesting that the
RGDS anti-proliferative action requires, at least in part,
survivin presence. To further confirm such hypothesis,
the opposite approach was followed, and survivin-forced
expression was achieved by transfection with a specific
expression plasmid. Western blotting analysis confirms
survivin overexpression as compared to the control (Fig-
ure 5B top); under such experimental conditions FGF-2
Figure 2 RGDS internalization in melanoma cells. A: Bt-RGDS inter-
nalization into live SK-MEL-110 was examined after 24 h incubation at 
37°C. Cells were treated with biotin alone or with increasing concen-
trations of bt-RGDS, cytoplasmic extracts were immobilized onto nitro-
cellulose and biotin presence was detected by avidin-peroxidase kit. 
Densitometry-quantification of total internalization in three experi-
ments and one representative experiment are reported. B: Total inter-
nalization measured in extracts obtained from cells treated with bt-
RGDS (50 μg/ml), and nonspecific internalization in the presence of an 
excess of unlabeled RGDS (1 mg/ml). Densitometry of three separate 
experiments and one representative experiment are reported. C: Bt-
RGDS internalization (500 μg/ml) at 24 h was confirmed by confocal 
microscopy (original magnification × 40). RGDS entered into live mel-
anoma cells (green stain) with a prevalently cytoplasmic localization. 
Nuclei are shown as blue stain. This experiment was carried out three 
times in duplicate.
Figure 3 RGDS-survivin interaction. A: Bt-RGDS interaction with cell 
lysate: cytoplasmic extracts were immobilized onto nitrocellulose and 
incubated with bt-RGDS. Total binding in the presence of labeled 
RGDS and nonspecific binding in the presence of an excess of unla-
beled RGDS are shown. Densitometry of three different experiments 
and one representative experiment are reported. B: RGDS interaction 
with intracellular proteins was assayed by co-precipitation. BSA (con-
trol), bt-RGES (specificity control) or bt-RGDS (1 mM) were incubated 
for 1 h at 4°C with streptavidin-coated dynabeads, then SK-MEL-110 
lysate, pre-incubated for 4 h at 4°C with an excess of unlabeled RGDS, 
was added and incubated overnight at 4°C. Precipitated proteins were 
revealed by western blotting using various antibodies (anti pro-cas-
pase-8, anti pro-caspase-9, anti pro-caspase-1, anti pro-caspase-3 and 
anti-survivin). Total lysate was used as positive control. This experiment 
was carried out three times. C: Purified recombinant proteins were 
spotted onto nitrocellulose (0.9 μg/spot). Membrane was incubated 
for 4 h at RT with bt-RGDS (1 mg/ml) (total binding) in the absence or 
in the presence of an excess of unlabeled RGDS (10 mg/ml) (nonspe-
cific binding). Three independent experiments were performed.Aguzzi et al. Molecular Cancer 2010, 9:84
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survival effect is increased, as expected, and RGDS main-
tains its anti-mitogenic effect (Figure 5B bottom).
RGDS effect on caspase-3 expression
We and Others previously demonstrated that RGDS acti-
vates caspase-3 in different cell types [3,22,23], leading to
apoptosis. In the present study 48 h RGDS treatment
reduced pro-caspase-3 (molecular weight 32 kDa) and
increased expression of caspase-3 active subunit (17 kDa)
in SK-MEL-110 (Figure 6A top). Caspase-3 activation was
confirmed by confocal microscopy using a specific anti-
body able to recognize the active form, while RGES con-
trol peptide had no effect on caspase-3 activation (Figure
6A bottom). Pre-treatment of melanoma cells for 2 h with
Z-VAD-FMK, a general caspases inhibitor, significantly
abolished the RGDS anti-proliferative effect (Figure 6B),
further indicating that RGDS action was caspase-depen-
dent.
Discussion
The RGD motif occurs in several ECM proteins and plays
a crucial role in integrin-mediated cell adhesion. It has
been largely investigated in the past decades as mediator
of integrins-dependent cell-adhesion and, consequently,
for the effect on survival, invasion, blood coagulation
[21,34,35]. Recent evidence by different investigators has
identified a novel role, namely the RGD ability to act at
the intracellular level, to recognize intracellular targets
and to activate the apoptotic cascade via a direct caspase-
activation process and caspase cleavage [3,22-24]. Thus a
possible role of RGD-containing peptides released from
the extracellular matrix and accumulated in the cytosolic
compartment has been suggested [36], highlighting the
view that extracellular matrix degradation occurring dur-
ing physiologic and pathologic tissue-remodeling, may
generate RGD-containing products acting at the intracel-
lular-level.
W e have previously demonstra ted tha t under experi-
mental conditions most-likely abrogating extracellular
anti-adhesive effect, RGDS induces apoptosis in HUVEC
in integrins-independent way and directly interacts with
caspase-8 and caspase-9 in HUVEC [3]. RGDS peptide
has been studied in several melanoma setting, mostly as
an anti-adhesion molecule [37-39], while no data are
available on the intracellular effect of RGDS in melanoma
cells. Hence we addressed RGDS internalization in these
cells and investigated novel intracellular targets involved
in the control of melanoma cells survival. Cell adhesion to
collagens is RGD-independent [2-4]; thus, in cells seeded
onto collagen-IV most of the RGDS biological effects do
not depend on its anti-adhesive effects. Under such con-
ditions, RGDS significantly inhibited proliferation of SK-
MEL-110 in the presence of FGF-2 and induced apopto-
sis, while the control-peptide RGES was ineffective.
RGDS peptide was internalized into live melanoma cells
and specifically interacted with the cytoplasmic extract.
RGDS-internalization and anti-mitogenic/pro-apoptotic
effects were observed in melanoma cells (in the present
study) and in HUVEC [3], although kinetics and potency
are different due to the different intrinsic features of these
two cell types. Interestingly, RGES peptide did not show
biological effects but was internalized, although with
s l o w e r  k i n e t i c s  c o m p a r e d  t o  R G D S .  T h i s  o b s e r v a t i o n
agrees with previous data collected on other RGDS con-
trols [23] and opens the question regarding mechanisms
of internalization and its specificity. Further investiga-
tions are needed to discriminate between passive diffu-
sion of small molecules such as RGES and RGDS, and
specific-RGDS-internalization [40]. RGDS directly and
specifically bound pro-caspase-8, pro-caspase-9 and pro-
caspase-3, while it did not bind pro-caspase-1, a pro-
inflammatory caspase not directly involved in the apop-
tosis cascade. Such data may support the hypothesis that
Figure 4 RGDS-survivin binding. A: Increasing doses of purified hu-
man-recombinant survivin (0.3 to 5 μg/spot) were immobilized onto 
membrane and incubated with bt-RGDS in the presence of un-labeled 
peptide, as competitor (top). A representative experiment of two differ-
ent assays, is shown. Densitometry quantification is reported (bottom). 
B: Bt-RGDS binding to recombinant GST-fusion survivin and to N-ter-
minus (Met1-Gly99) or C-terminus (Lys90-Asp142) fragments (175 mM) 
was evaluated by solid-phase assay (SPA). Proteins were immobilized 
onto plastic and were incubated with increasing doses of bt-RGDS 
(1.75 nM to 1.75 mM) in the presence of an excess of un-labeled RGDS. 
Three independent experiments were performed.Aguzzi et al. Molecular Cancer 2010, 9:84
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intracellular targets of RGDS may comprise different
molecules of the apoptotic cascade. Conversely, RGES did
not interact with any tested intracellular target. Survivin
was found to be a novel RGDS intracellular direct target
and a specific RGDS-binding site was found at survivin
C-terminus, where an extended alpha-helical coiled-coil
portion is located. Such domain is known to play a key
role for the survivin interaction with microtubules and
cell division-control. Additional studies will be carried
out to identify the specific amino acids involved in
RGDS-survivin interaction. Survivin controls cell divi-
sion, apoptosis and cellular stress response and protects
cells against both caspase-dependent and caspase-inde-
pendent cell death [41,42]. Its interaction with RGDS
although un-expected, was not surprising, given the pre-
vious evidence showing direct interaction of RGDS with
other key players of the survival/apoptosis machine
[3,22,23]. Survivin-silencing achieved with a specific
siRNA suppressed the anti-mitogenic action of RGDS,
while the anti-proliferative effect of RGDS was main-
tained when survivin expression was up-regulated with a
specific expression plasmid, indicating that survivin is
required for RGDS anti-mitogenic effect in SK-MEL-110
and that cell-sensitivity to RGDS actions may depend at
least in part on survivin levels in different physiological
and pathological conditions. Such consideration supports
survivin as a potential target for anti-tumor approaches.
Indeed, several studies demonstrated that anticancer
drugs as colecoxib, COX-2 inhibitors or silibilin derivates
down-regulate survivin expression in a wide range of
tumor cells, inducing apoptosis [43,44].
Conclusions
The present study indicates that in melanoma cells RGDS
peptide interacts with intracellular targets, namely apop-
totic caspases and survivin; identifies RGDS as a survivin-
targeting molecule and indicates a novel mechanism to
control cell proliferation.
Methods
Cells culture
Human metastatic melanoma cells line SK-MEL-110 [45]
were grown in DMEM (Hyclone, Logan, UT) supple-
mented with 2 mM L-glutamine, 100 IU/ml penicillin-
streptomycin (Gibco, Invitrogen corporation, Carlsbad,
CA), and 10% heat-inactivated FCS (Hyclone, Logan,
UT). Cells were cultured at 37°C in a 5% CO2 atmosphere.
Figure 5 RGDS effect require survivin expression. SK-MEL-110 were transfected with human survivin siRNA or with control siRNA before RGDS 
treatment. SiGLO Lamin A/C siRNA was used as control of transfection efficiency. A Top: Survivin silencing was confirmed by western blotting after 72 
h transfection. Bottom: FGF-2 (10 ng/ml)-induced proliferation in survivin-silenced or in control, after RGDS treatment for 48 h (* p < 0.05 vs FGF-2 and 
# p < 0.005 vs FGF-2 in silenced cells). Three independent experiments were performed in duplicate. B Top: Full length HA-tagged survivin was over-
expressed in melanoma cells before RGDS treatment. Over-expression was confirmed by western blotting after 24 h transfection. Bottom: RGDS effect 
on FGF-2-induced proliferation in transfected-SK-MEL-110 after 48 h treatment (p < 0.01 vs FGF-2). Three independent experiments were performed 
in duplicate.Aguzzi et al. Molecular Cancer 2010, 9:84
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Proliferation assay and apoptosis
SK-MEL-110 were plated in 6-well plates (8 × 104 cells/
well) on collagen-IV (50 μg/ml) and were grown for 24 h
in complete medium in 5% CO2. Cells were then serum-
starved for 24 h and subsequently treated with RGDS
(Bachem, Bubendorf, Switzerland) or RGES as control
(Sigma-Aldrich, St Louis, MO) (500 μg/ml) dissolved in
DMEM containing FGF-2 (Pierce-Endogen, Rockford, IL)
for 48 h. Then, cells were photographed, harvested by
trypsin-EDTA and counted using hemacytometer. In
other experiments, cells were pre-treated with a general
caspase inhibitor (Z-VAD-FMK) (50 μM) (R&D Systems,
Minneapolis, MN) for 2 h before RGDS treatment. To
analyze cell cycle and sub-G1-phase, cells were fixed in
ice-cold 70% ethanol and stained with propidium iodide
(PI) at 10 μg/ml final concentration. Flow cytometry was
performed on a Profile I flow cytometer (FACSCalibur,
BD-Biosciences).
Biotinylated-RGDS (bt-RGDS) internalization and 
interaction with recombinant proteins
To investigate peptides internalization, cells were treated
with the biotinylated-RGDS (bt-RGDS) or biotinylated-
RGES (bt-RGES) (NeoMPS-SA, Strasbourg, France) as
control for different time-points, stained with phyco-
erythrin conjugated-avidin and analyzed by FACS. In
additional experiments cells grown on collagen-IV were
serum-starved for 48 h and treated for 24 h with biotin
alone or with different doses of bt-RGDS (10-50-100 μg/
ml). In other experiments cells were treated with 50 μg/
ml bt-RGDS with an excess of 1 mg/ml un-labeled RGDS
as specific competitor. Cells were washed to eliminate bt-
RGDS bound to the membranes and a cytoplasmic
e x t r a ct  was  p r e pa r ed  as  p r evi o us l y  r e po rt ed [ 3 ] .  C yt o -
plasmic lysates were spotted onto nitrocellulose, blocked
with 5% milk in TPBS (0.1% Tween 20 in PBS) and incu-
bated for 1 h at RT with a Vectastain ABC-peroxidase kit
(Vector) followed by chemiluminescence reaction and
e x p o s u r e  t o  K o d a k  f i l m  ( E a s t m a n  K o d a k ) .  I n t e r a c t i o n
was quantified by densitometry (GS 710; Bio-Rad) and
analyzed using the "Quantity one" software (Bio-Rad).
In other experiments 40 μg of growing cells cytoplas-
mic extract, or increasing doses of recombinant human
survivin (0.3-0.9-1.5-3-5 μg) (CP-Biotech, Sylvania, OH)
or other recombinant proteins, as caspases-1 and -9, pro-
caspase-9 (Alexis), fibronectin (0.9 μg) (Becton-Dickin-
son, Bradford, MA) and BSA were spotted onto nitrocel-
lulose, incubated for 4 h at RT with bt-RGDS (1 mg/ml) in
the presence or absence of RGDS-excess (10 mg/ml) to
measure the specific binding.
Confocal microscopy
SK-MEL-110 seeded on coverslips coated with collagen-
IV and treated for 24 h with bt-RGDS (500 μg/ml), were
washed as previously reported to eliminate the peptide
bound to the membranes [3]. Cells were fixed with 3%
Figure 6 RGDS treatment activates caspase-3. A: SK-MEL-110 seeded on collagen-IV were incubated for 48 h with FGF-2 in the presence or in the 
absence of RGDS or RGES (500 μg/ml). Top: Pro-caspase 3 cleavage and caspase-3 activation were observed by western blotting. Bottom: caspase-3 
activation was confirmed by confocal microscopy using an anti-active caspase-3 antibody. B: Pre-treatment (2 h) of melanoma cells with Z-VAD-FMK 
(50 μM), a general caspases inhibitor, abolished the RGDS anti-proliferative effect (p < 0.005 vs FGF-2 in the presence of Z-VAD-FMK). All these exper-
iments were carried out three times in duplicate.Aguzzi et al. Molecular Cancer 2010, 9:84
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paraformaldehyde in PBS, pH 7.4, for 10 minutes, perme-
abilized with 0.1% Triton X-100 in PBS, pH 7.4, for 5 min-
utes at RT, and blocked for 30 minutes with BSA 2% in
PBS, pH 7.4, at RT, followed by incubation with fluores-
cein avidin (1:40; Vector-Laboratories, Peterborough,
UK) in PBS, pH 7.4, for 1 h at RT. After washing in 0.3%
Triton X-100 in PBS, cells were incubated with PI at a
final concentration of 5 μg/ml to visualize nuclei and ana-
lyzed using a Zeiss LSM 510 meta-confocal microscope
(Zeiss). Laser power, beam splitters, filter settings, pin-
hole diameters and scan-mode were the same for all
examined samples. To visualize active caspase-3 form,
cells were treated with RGDS or RGES, fixed and incu-
bated with a rabbit-monoclonal anti-active caspase-3
(1:150) (Abcam Inc,. Cambridge, MA).
Western blotting
SK-MEL-110 treated as described in the proliferation
assay paragraph, were lysed with RIPA buffer. Samples
were boiled, loaded and separated by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to nitrocellulose membrane. Membrane was
blocked with 5% milk (Bio-Rad Laboratories) in TPBS
(0.1% Tween 20 in PBS, pH 7.4), washed and incubated
with mouse anti-survivin (1:200) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), rabbit anti-caspase 3 (1:200) (Santa
Cruz Biotechnology, Alexa, CA,), or mouse anti-β-actin
(1:5000) (Sigma-Aldrich, St Louis, MO) in milk 5% TPBS
0.1% for 1 h at RT. Horseradish peroxidase-conjugated
secondary antibodies (Pierce) were used, followed by
chemiluminescence (ECL; Amersham, Buckinghamshire,
United Kingdom) and autoradiography.
Precipitation with streptavidin-coated Dynabeads
Streptavidin-coated Dynabeads (M-270, 2.8 μm, Dynal)
were re-suspended, washed in PBS three times, using a
magnetic holder, re-suspended and 1 × 103 pmoles of bt-
RGDS, BSA or bt-RGES per mg beads were added, incu-
bated for 1 h at 4°C and washed in PBS for five times.
Growing SK-MEL-110 were lysed as reported [22], pre-
incubated with 10 μl RGDS as specific competitor (1
mM) and incubated with activated beads, at 4°C over-
night with unidirectional mixing. Samples were boiled
and separated by SDS-PAGE as described above and
incubated with antibody to survivin (1:200), caspase-3
(1:200), caspase-8 (1:200) (Santa Cruz Biotechnology,
Alexa, CA), caspase-9 (1:1000) (Pharmingen, San Diego,
CA), caspase-1 (1:500) (Alexis, San Diego, CA). Detection
was performed as described above.
Survivin cloning and expression
Full length HA-tagged Survivin cDNA (GeneBank
NM_001168) was generated by PCR using total cDNA
from HeLa cells as template.
The primers used were:
GATCAAGCTTATGTATCCGTATGATGTTCCT-
GATTATGCTGGTGCCCCGACGTTGCC (forward)
and GATCGGATCCGGAAGTGGTGCAGCCACTC
(reverse) (Invitrogen).
Restriction sites (underlined) for the endonucleases
HindIII and BamHI were used for cloning in pcDNA3
vector (Invitrogen). All constructs made by PCR were
sequence-verified. Recombinant HA-survivin was
expressed in SK-MEL-110 by transient transfection using
Lipofectamine Plus Reagent (Invitrogen) according to the
manufacturer's instruction. pcDNA-HA empty vector
was used as control. Transfection efficiency was evalu-
ated using a pEGFP-N1 reporter vector at a HA-survivin
plasmid molar ratio of 4:1. FGF-2-induced proliferation
in transfected cells was evaluated after RGDS 48 h treat-
ment. Protein expression was detected by western blot-
ting.
Full length survivin and both N-terminus (Met1-Gly99)
or C-terminus (Lys90-Asp142) were PCR amplified and
cloned, using EcoRI and BamHI restriction sites, in
pGex6P2 (GE Healthcare) for expression of GST fusion
proteins in E. coli BL21(DE3)pLysS (PROMEGA, South-
ampton, United Kingdom).
The primers used were:
GATGGATCCATGGGTGCCCCGACGTTGC (Met1
forward),
GATGAATTCTCAATCCATGGCAGCCAGCTG
(Asp142 reverse),
GATGAATTCTCAACCAAGGGTTAATTCT-
TCAAAC (Gly99 reverse) and
GATGGATCCAAGAAGCAGTTTGAAGAATTAAC
(Lys90 forward).
GST -fusion proteins were verified by SDS-P AGE and
Coomassie staining and their concentration was deter-
mined by Bradford protein-assay.
Solid Phase Assay
Bt-RGDS binding to recombinant GST-fusion proteins
was evaluated by solid-phase assay (SPA) as previously
described [46] with modifications. Briefly, microtiter
plates (Costar, Cambridge, MA) were coated with 175 nM
(100 μl/well) recombinant GST-fusion proteins diluted in
AC7.5 buffer for 4 h at RT. Wells were blocked in 30 mg/
ml BSA (300 μL/well) overnight at 4°C, washed and incu-
bated for 4 h at RT with increasing doses of bt-RGDS
(from 1.75 to 1.75 mM), in the presence or in the absence
of an excess of not-biotinylated RGDS, as specific com-
petitor. After washing four times and incubation for 1 h at
RT with 100 μl/well Vectastain-ABC Reagent (Vector
Laboratories, Burlingame, CA), wells were stained with
the ELISA Amplification System (Invitrogen, Carlsbad,
CA) according to manufacturer's instructions and
absorption at 495 nm (A495) was determined. SpecificAguzzi et al. Molecular Cancer 2010, 9:84
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binding was computed by subtracting nonspecific from
total binding at each concentration. Curve fit was carried
out according to the following one-site specific bind
equation (GraphPad Prism-4 software):
where X is ligand concentration, Y is the specific bind-
ing, Bmax is the maximum specific binding in the same
units as Y, Kd is the equilibrium binding constant, in the
same units as X.
siRNA interference assays
SK-MEL-110 were seeded in 6-well-plates on collagen-IV
(1 × 105 per well). Twenty-four hours later cells were
transfected with human survivin siRNA (100 nM) or con-
trol siRNA-A (Santa Cruz Biotechnology) using Lipo-
fectamine Plus Reagent according to manufacturer's
instructions. SiGLO Lamin A/C siRNA (Dharmacon-
RNAi Technologies) was used as control of transfection
efficiency. After 72 h silencing, cells were treated for 48 h
with FGF-2 (10 ng/ml) in the presence or in the absence
of RGDS (500 μg/ml). Cells were counted using hemacy-
tometer. Silencing of survivin protein was confirmed by
western blotting.
Statistics
Data were expressed as mean ± S.D. Student's two-tailed t
test was performed and p ≤ 0.05 was considered statisti-
cally significant.
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